Callan Capital LLC Takes $209,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Callan Capital LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 1,982 shares of the medical equipment provider’s stock, valued at approximately $209,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZBH. Roman Butler Fullerton & Co. bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $473,000. Geode Capital Management LLC grew its position in Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after purchasing an additional 125,852 shares during the period. M&T Bank Corp raised its holdings in Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after buying an additional 8,709 shares during the last quarter. KLCM Advisors Inc. bought a new position in shares of Zimmer Biomet in the fourth quarter valued at $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at about $654,000. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ZBH shares. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Wells Fargo & Company increased their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $104.89 on Monday. The stock has a fifty day simple moving average of $105.86 and a two-hundred day simple moving average of $107.46. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The firm has a market cap of $20.88 billion, a price-to-earnings ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm posted $2.20 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.